Tags : Hematological


Roche Signs an Agreement with Innovent to Develop Therapies for

Shots: Roche to receive upfront, development and commercial milestone payments plus royalties and retains option to license for each ex-China development and commercialization. Innovent to get non-exclusive access to certain technologies of Roche to discover and develop specific 2:1 T-cell bispecific Abs (TCB) and the universal CAR-T platform If Roche exercise the option, it will […]Read More


AbbVie Licenses Lupin’s MALT1 Inhibitor Program, for $977M

Shots: Lupin to receive $30M upfront, up to $947M milestones and royalties on sales. AbbVie to get exclusive worldwide (Ex. India) rights to develop and commercialize Lupin’s MALT1 inhibitors The focus of the agreement is to utilize Lupin’s Drug Discovery platform to develop treatments for multiple hematological cancers MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) Inhibitor Program involves protein […]Read More